[
    [
        {
            "time": "2018-08-22",
            "original_text": "Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "EXAS",
                    "PFE",
                    "ARGX",
                    "PHG",
                    "SNGX"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "ARGX",
                    "PHG",
                    "SNGX"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "AbbVie Is Focused on Diversifying Its Portfolio in 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Diversifying",
                    "Portfolio",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Is Focused on Diversifying Its Portfolio in 2018",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "Oncology Is a Major Growth Driver for AbbVie in 2018",
            "features": {
                "keywords": [
                    "Oncology",
                    "Growth",
                    "Driver",
                    "AbbVie",
                    "2018"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Oncology Is a Major Growth Driver for AbbVie in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "European shares steady as trade talks, U.S. politics fuel uncertainty",
            "features": {
                "keywords": [
                    "European",
                    "shares",
                    "steady",
                    "trade",
                    "talks",
                    "U.S.",
                    "politics",
                    "uncertainty"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "European shares steady as trade talks, U.S. politics fuel uncertainty",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "AbbVie Has Raised Its EPS Guidance for 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Raised",
                    "EPS",
                    "Guidance",
                    "2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Has Raised Its EPS Guidance for 2018",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug",
            "features": {
                "keywords": [
                    "Argenx",
                    "Shares",
                    "Up",
                    "AbbVie",
                    "Option",
                    "License",
                    "Immuno-Oncology",
                    "Drug"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Positive",
                    "Topline",
                    "Results",
                    "Phase",
                    "3",
                    "Extension",
                    "Study",
                    "Elagolix",
                    "Uterine",
                    "Fibroids"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Positive",
                    "Results",
                    "Phase",
                    "3",
                    "Extension",
                    "Study",
                    "Elagolix"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-08-22",
            "original_text": "AbbVie doubles down on cancer project with biotech group Argenx",
            "features": {
                "keywords": [
                    "AbbVie",
                    "doubles",
                    "down",
                    "cancer",
                    "project",
                    "biotech",
                    "group",
                    "Argenx"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie doubles down on cancer project with biotech group Argenx",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]